论文部分内容阅读
AIM:To assess feasibility,tolerability and efficacy of gemcitabine-based chemotherapy in patients≥75 years old with advanced pancreatic cancer.METHODS:All consecutive patients≥75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study.Necessary criteria to receive chemotherapy were:performance status 0-2,adequate biological parameters and no serious comorbidities.Other patients received best supportive care(BSC).RESULTS:Thirty-eight patients(53%women,median age 78 years,range 75-84)with pancreatic cancer(metastatic:n=20,locally advanced:n=18)were studied.Among them,30(79%)were able to receivechemotherapy[median number:9 infusions(1-45)].Six patients(23%)had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome.No toxic death occurred.Three patients(11%)had a partial tumor response,13(46%)had a stable disease and 12(43%)had a tumor progression.Median survival was 9.1 mo(metastatic:6.9 mo,locally advanced:11.4 mo).CONCLUSION:Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition,with similar results to younger patients.
AIM: To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥75 years old with advanced pancreatic cancer. METHODS: All consecutive patients ≥75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC) .RESULTS: Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer Six patients (23%) had at (30%) were able to receive chemotherapy (median number: 9 infusions (1-45)] had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had more than one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome ) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo). CONCLUSION: Tolerance and efficacy of gemcitabine-based chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.